In order to focus its resources on its lead antibody-drug conjugate (ADC) and an array of Big Pharma partnerships, CytomX is considering the future of the Amgen ... $300 million off the value ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback